ORLANDO—Clinicians are less likely to use evidence-based therapies for congestive heart failure (CHF), especially ACE inhibitors or angiotensin receptor blockers (ARBs), when their patients also have renal dysfunction, a study found.
Renal disease progresses more slowly in women than men even though women have a lower estimated glomerular filtration rate (eGFR) at the time of referral to a nephrologist, according to Canadian researchers.
CKD patients with coronary artery calcification (CAC) are at increased risk for renal function decline, according to investigators at Queen’s University in Kingston, Ont.
Telmisartan plus amlodipine is superior to losartan plus amlodipine in reducing microalbuminuria in hypertensive patients with type 2 diabetes, Italian researchers reported.
Renal function plays a role in warfarin response, according to a study conducted at the University of Alabama in Birmingham.
Hyperuricemia increases the risk of death from any cause and from cardiovascular disease (CVD) in patients with CKD stages 3 to 4, according to a report in the American Journal of Kidney Diseases (2009; published online ahead of print).
Elevated serum phosphate levels are associated with all-cause and cardiovascular mortality in patients on dialysis, as demonstrated in a 2004 study by Block and colleagues (J Am Soc Nephrol. 2004;15:2208-2218).
NASHVILLE—Patients who enroll in a structured CKD program that provides pre-dialysis interventions may improve their survival in the first year after starting dialysis, data suggest.
Use of the Modification of Diet in Renal Disease (MDRD) study formula may overestimate the number patients with renal dysfunction, according to researchers at the Roswell Park Cancer Institute in Buffalo.
BP-lowering may provide renoprotection in patients with type 2 diabetes, regardless of baseline BP level.
